乳腺癌
小RNA
癌变
肿瘤科
抗药性
医学
癌症
精密医学
生物信息学
个性化医疗
转移
内科学
癌症研究
生物
基因
遗传学
病理
作者
Thanh Hoa Vo,Esam EL-Sherbieny Abdelaal,Emmet Jordan,Orla O'Donovan,Edel A. McNeela,Jai Prakash Mehta,S. Sirisha Rani
标识
DOI:10.1016/j.bbrep.2023.101588
摘要
Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20–25 % of all breast cancer and is rather aggressive. Although the treatment outcome of HER2+ breast cancer patients has been significantly improved with anti-HER2 agents, primary and acquired drug resistance present substantial clinical issues, limiting the benefits of HER2-targeted treatment. MicroRNAs (miRNAs) play a central role in regulating acquired drug resistance. miRNA are single-stranded, non-coding RNAs of around 20–25 nucleotides, known for essential roles in regulating gene expression at the post-transcriptional level. Increasing evidence has demonstrated that miRNA-mediated alteration of gene expression is associated with tumorigenesis, metastasis, and tumor response to treatment. Comprehensive knowledge of miRNAs as potential markers of drug response can help provide valuable guidance for treatment prognosis and personalized medicine for breast cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI